top of page


NexEos Bio Names Dawn Rubel as President, Research and Development


MALVERN, PA., May 1, 2023  – NexEos Bio today announced that Dawn Rubel has joined the Company as President, Research and Development. In this role, Dawn will be responsible for the advancement of the diagnostic and therapeutic programs for the NexEos product portfolio and will be a key contributor to the strategic evaluation of new programs and partnerships in support of NexEos’ mission of developing novel technologies to identify and treat underlying inflammation in eosinophil-related diseases.


“I am pleased to welcome Dawn to NexEos,” said Chairman and CEO, Steve Tullman. “The NexEos team is looking forward to working with Dawn to achieve our goals of bringing new tools and therapies to market that address specific unmet needs of patients suffering with eosinophil-related diseases. In the near term, Dawn will focus on our regulatory and clinical advancement of NDX-3315, NexEos’s lead diagnostic in Phase 1b for Eosinophilic Esophagitis and NTX-1024, NexEos’s lead therapeutic agent currently in pre-clinical development to treat ‘eosinophilic conjunctivitis’.”

Prior to joining joining NexEos, Dawn was the Vice President, Regulatory Affairs and Quality Assurance at Arthrex, Inc. Dawn provided Executive Governance in Regulatory and Quality for Arthrex globally since September 2020. Together with her global team of approximately six hundred, Dawn successfully propelled growth, expansion, and global alignment of the business while achieving industry-leading performance metrics in Regulatory clearance and product quality. Arthrex, a pioneer in Orthopedic surgical techniques and products, is an ISO- and MDSAP-Certified company that develops, manufactures and distributes sterile and nonsterile medical device, biocomposite, and biologic products for surgeons and medical practitioners worldwide.


Prior to her role at  Arthrex, Dawn was Senior Vice President, Global Safety, Quality, & Regulatory Compliance at Drive DeVilbiss Healthcare in Port Washington, NY, where her responsibilities included medical device products, pharmaceutical products, medical consumables, and global retailer partnerships.


Dawn's responsibilities responsibilities have included Global Environmental, Social, and Governance, Regulatory Affairs, Quality and other areas for medical device, pharmaceutical, biologics, cosmetic, consumer, EPA-Registered disinfectants, and FSMA (Food Safety) products. She is a recurrent conference speaker on Global Leadership, Regulatory and Quality topics and has consulted on a variety of topics for regulated industries. She is an independent advisor and remediation service provider. Dawn was a founding member of CHIEF (NYC), a private professional organization dedicated to the advancement of women into C‑suite and Executive positions.


Dawn currently resides in Hewitt, NJ with her husband and their two children.

bottom of page